Yuchun Lee - Jan 27, 2023 Form 4 Insider Report for VERTEX PHARMACEUTICALS INC / MA (VRTX)

Role
Director
Signature
/s/ Christiana Stevenson, Attorney-in-Fact
Stock symbol
VRTX
Transactions as of
Jan 27, 2023
Transactions value $
-$357,089
Form type
4
Date filed
1/31/2023, 03:42 PM
Previous filing
Jan 27, 2023
Next filing
May 3, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VRTX Common Stock Options Exercise $103K +1.43K +76.21% $72.14 3.3K Jan 27, 2023 Direct
transaction VRTX Common Stock Sale -$122K -379 -11.47% $321.31 2.93K Jan 27, 2023 Direct F1, F2, F3
transaction VRTX Common Stock Sale -$313K -970 -33.16% $322.20 1.96K Jan 27, 2023 Direct F1, F2, F4
transaction VRTX Common Stock Sale -$25.9K -80 -4.09% $323.33 1.88K Jan 27, 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction VRTX Stock Option (Right to Buy) Options Exercise $0 -1.43K -100% $0.00* 0 Jan 27, 2023 Common Stock 1.43K $72.14 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Transaction made pursuant to Mr. Lee's company approved trading plan under Rule 10b5-1.
F2 Mr. Lee undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
F3 Open market sales reported on this line occurred at a weighted average price of $321.31 (range $320.62 to $321.59).
F4 Open market sales reported on this line occurred at a weighted average price of $322.20 (range $321.75 to $322.74).
F5 Fully vested.